Who is filing in nano-delivery? Tracking the top assignees in encapsulation and targeted-release patent classes
Knowing who is filing tells you where the money and the fights are heading. Here is what current data shows and how to track it yourself.
Patent filings are one of the earliest public signals of where a company is investing. In nano-delivery, they also tell you where the next disputes are likely to be. This brief looks at who is active, what the data can and cannot tell you, and how we track it.
What the classes cover
Nano-delivery work is spread across several classification codes. The most useful to watch include IPC A61K 9/50 (microcapsules) and A61K 9/51 (nanocapsules), A61K 9/127 for liposomes and related bilayer vehicles, and the CPC code B82Y 5/00 for nanomedicine and drug delivery. Excipient and carrier chemistry also appears under A61K 47. Watching codes, rather than keywords, catches filings that describe the same thing in different words.
Who is active
A 2026 landscape published by PatSnap, drawn from a limited set of retrieved records rather than a complete count, found Genentech with 11 lipid-nanoparticle manufacturing filings between 2022 and 2025 across multiple jurisdictions, followed by Pfizer and the Mayo Foundation with five or more each, and Generation Bio and Abraxis/Celgene with four each. In the same dataset, ionizable lipid nanoparticles made up 42% of filing clusters, polymeric nanoparticles 28%, protein-carrier nanoparticles 18% and inorganic or hybrid particles 12%. Japan showed the most activity, followed by Israel, China and international (PCT) filings, and at least ten Chinese academic institutions held active filings.
Litigation tells the other half of the story. The companies defending or asserting delivery patents most visibly in 2026 include Arbutus and Genevant, Moderna, Pfizer and BioNTech, and Alnylam. Their portfolios are worth watching for continuations, because new claims are often written with competitors' products in mind.
Reading the data carefully
- Counts are not quality. One foundational patent can matter more than fifty incremental ones.
- Names change. Acquisitions, subsidiaries and licensing vehicles spread one portfolio across many assignee names. Normalise them before you rank anyone.
- Publication lags. Applications usually publish about eighteen months after filing, so today's data describes decisions made a year and a half ago.
- Academia matters. Universities and hospitals file early and license later. Their filings are often the best leading indicator.
How we track it
We keep a watchlist of the classes above, normalise assignee names, flag new continuations from litigating parties, and pair filings with clinical-trial and literature activity so a filing is never read in isolation. That combination of evidence and analysis is what our operating system is built to do. This brief is research and analysis, not investment or legal advice.